A phase 1-2 study of rovalpituzumab tesirine in combination with nivolumab plus or minus ipilimumab in patients with previously treated extensive-stage SCLC

Authors

Jyoti Malhotra, Rutgers University - New Brunswick/Piscataway
Daniel Morgensztern, Washington University School of Medicine in St. Louis
et al.

Journal

Journal of Thoracic Oncology

Publication Date

9-1-2021

Volume

16

Issue

9

First Page

1559

Last Page

1569

Document Type

Open Access Publication

DOI

10.1016/j.jtho.2021.02.022

Rights and Permissions

Malhotra J, Nikolinakos P, Leal T, Lehman J, Morgensztern D, Patel JD, Wrangle JM, Curigliano G, Greillier L, Johnson ML, Ready N, Robinet G, Lally S, Maag D, Valenzuela R, Blot V, Besse B. A Phase 1-2 Study of Rovalpituzumab Tesirine in Combination With Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Extensive-Stage SCLC. J Thorac Oncol. 2021 Sep;16(9):1559-1569. doi: 10.1016/j.jtho.2021.02.022. Copyright 2021 International Association for the Study of Lung Cancer. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)

Recommended Citation

Malhotra, Jyoti; Morgensztern, Daniel; and et al., "A phase 1-2 study of rovalpituzumab tesirine in combination with nivolumab plus or minus ipilimumab in patients with previously treated extensive-stage SCLC." Journal of Thoracic Oncology. 16, 9. 1559 - 1569. (2021).
https://digitalcommons.wustl.edu/oa_4/1489

Department

ICTS (Institute of Clinical and Translational Sciences)